ABSTRACT In a double-blind randomized trial involving five Sydney hospitals and the city ambulance paramedical service, 145 patients with a first evolving myocardial infarction and with onset of pain less than 2.5 (mean 1.9 + 0.5 [SD]) hr previously were allocated to intravenous infusion of 100 mg recombinant tissue-type plasminogen activator (rt-PA) 
tom onset through a double-blind, placebo-controlled clinical trial. Infarct size was assessed by measurement of left ventricular global ejection fraction at 21 days after coronary occlusion with the use of both contrast ventriculography and radionuclide ventriculography.
Methods
Patients and logistics at entry. The study was designed as a collaborative effort between Sydney's Central District Ambulance service and five major city hospitals. The ambulance control center was notified by ambulance officers called to a patient with suspected coronary occlusion and in turn advised a staff member at the appropriate hospital who was on 24 hr call. The staff member either proceeded to the patient in another ambulance or arranged to meet the ambulance on arrival at the hospital's emergency department. A history was taken and an electrographic (ECG) recording obtained expeditiously outside the hospital or in the emergency department, and the patient was considered for entry into the trial. Patients fulfilling all criteria were offered participation; those agreeing were entered after informed consent had been obtained. Patients The end point of the trial was planned as observation of a statistically significant difference in left ventricular ejection fraction by both contrast and radionuclide ventriculography in rt-PA and placebo-treated patients. At the time the trial commenced, it was considered that 100 to 200 patients should provide such a result. This prediction was based on the result of the Auckland streptokinase trial5 that the difference in angiographically determined ejection fraction due to very early intervention with an effective thrombolytic agent should be at least 5% above a value for placebo-treated patients of approximately 53 14%. We planned to perform an interim analysis soon after 100 technically satisfactory ventriculograms had been obtained.
The 
Results
In the 17 month period from February 5, 1986 , to June 29, 1987, 145 patients were admitted to the trial and received the full therapeutic dose of rt-PA. Another two (described below) were major protocol violations and were not included in analysis. Seventy-four were randomized to rt-PA and 71 to placebo. Time to commencement of therapy after onset of symptoms was2.0 + 0.5(SD)hrforrt-PAand 1.9 + 0.5hrfor placebo. No patient had previous infarction. The groups were well matched with no significant difference between treated and control groups with respect to age, sex, anterior and inferior developing infarction, heart rate, or arterial pressure (table 1) or other important variables.
Two patients were withdrawn during infusion of trial therapy. One (assigned to rt-PA) developed ventricular tachycardia and was difficult to resuscitate after the initial 10 mg infusion; therapy was stopped because of potential bleeding hazards resulting from traumatic heart massage. The second, assigned to placebo at 75 min of ischemic pain, was withdrawn at the insistence of the attending physician who demanded unblinding after 70 min of therapy; this patient was electively placed on streptokinase. Both patients recovered; data from neither were included in the analysis.
The clinical variables that may indicate reperfusion considered to be less than 48 hr old. The patient had no evidence of neurologic damage in the days before death. The relationship of cerebral hemorrhage to the use of rt-PA, heparin, aspirin, and dipyridamole or cardiac massage is unclear. Blood transfusion was required in one other patient (assigned to rt-PA) for treatment of anemia without obvious bleeding. Follow-up contrast ventriculograms were perforned on 126 patients and radionuclide ventriculograms on 128 patients. Reasons for failure to obtain contrast ventriculograms were as follows: death before day 21 ventriculogram (n = 8), investigation declined (n = 4), ventriculogram technically unsatisfactory because of multiple ectopics or poor opacification (n = 5), and miscellaneous (n = 2). Time to contrast ventriculography was 21 ± 9 days. There was no difference in time to angiography between the two groups. There was a significant 7% difference in contrast ejection fraction (from 54 ± 14% to 61 + 13%, 2p = .006) in favor of the rt-PA group (table 5) . A smaller difference (4%) was noted in left ventricular ejection fraction determined by radionuclide ventriculography (from 48 ± 13% to 52 + 13%, 2p = .08). A benefit of rt-PA was shown both for patients with anterior infarcts (ST segment elevation in the precordial leads on admission) and those with inferior infarcts (ST elevation in leads II, III, and avF) by contrast ventriculography. Radionuclide ventriculography showed a significant benefit for patients with anterior infarcts only.
Coronary arteriograms were available for 131 patients, and were graded according to the Thrombolysis in Myocardial Infarction (TIMI) trial protocol.7 Patency (TIMI grade 2 or 3) was 81% (55/68) in the rt-PA group and 63% (40/63) in the control group.
Discussion
Our results are explicable from previous work that has shown early lysis of coronary thrombosis with rt-PA.7 10 Benefit with respect to ejection fraction has not, however, been reported after rt-PA, although it has been for streptokinase administered by the intravenous route.5 '6 In the TIMI study'1 there was no difference in global ejection fraction in patients treated with streptokinase and those receiving rt-PA, despite a significant difference in recanalization rates in favor of rt-PA. This may be due to the later intervention time of this study (up to 7 hr, mean 4.9 hr) after the onset of chest pain (although in the TIMI study there was no restriction of patients to first infarction, and ventriculography was performed before hospital discharge). In our study the time to intervention was very short (1.9 ± 0.5 hr). We interpret the results to indicate salvage of reversibly damaged myocardium with limitation of streptokinase6 and with rt-PA. 2 Plasminogen activator may be safer than streptokinase in this respect, but relative safety will only become apparent after comparative trials and long-term use.
Mortality rate was low in both groups (5.5% overall) at 21 days. This is similar to that in the American TIMI7 and European'`studies of rt-PA. A difference in mortality was not expected in this relatively small study. Reinfarction rate was low (6%) and comparable to that reported in the Auckland streptokinase trial.5 Neither study provides grounds for aggressive management with early angioplasty or coronary artery surgery after thrombolysis.
Since preparation of this report a similar study has been reported by Guerci et al. '3 In that investigation, however, there was no restriction to first infarction, ventriculography was performed on the tenth hospital day (when stunned-myocardium may still have been in the process of recovery), patients were entered up to 4 hr after onset of symptoms, two different types of rt-PA were used, and patients were randomized to angioplasty as well as to rt-PA. Both studies, however, showed similar benefit from rt-PA, and similar low mortality and complication rates. Both suggest, as did the Auckland study with streptokinase,5 a strategy of early thrombolysis with consideration of angioplasty or bypass at a later time.
